ABCL · AbCellera Biologics Inc. · Insider Trading

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $11.29 to $11.86. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.49 to $10.70. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $10.25 to $10.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

This transaction represents a charitable donation of 50,000 common shares made by Genworks 2 Consulting, Inc. on August 11, 2026.

These shares are held by Genworks 2 Consulting, Inc. The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2 Consulting, Inc. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.

The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on July 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on July 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on June 15, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $3.42 to $3.45. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $3.19 to $3.40. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

This transaction represents a charitable donation of 225,000 common shares the reporting person donated on December 18, 2025.

The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on December 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable at the 2026 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable at the 2026 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable at the 2026 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $2.12 to $2.23. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

This transaction represents a charitable donation of 286,000 common shares the reporting person donated on December 4, 2024.

The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $2.55 to $2.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.